Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 12 September 2017

Indication(s)

Synagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:
- Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
- Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.
- Children less than 2 years of age and with haemodynamically significant congenital heart disease.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

+ 1 more

Cystic Fibrosis

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

+ 1 more

Bedwetting

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000257
Orphan designation No
Date First Approved 13-08-1999
Type Medicinal product subject to medical prescription
Marketing authorisation holder AbbVie Ltd